A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen(Copenhagen University Hospital), Inge Marie Svane(Copenhagen University Hospital)
Cited by 205
Related Papers
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
Predictors of responses to immune checkpoint blockade in advanced melanoma
|Nature Communications|2017|201
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study
|European Heart Journal|2020|166
Checkpoint inhibitors in breast cancer – Current status
|Cancer Treatment Reviews|2017|152